ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 001176

COMT inhibitors in Parkinson's disease

Identifieur interne : 001176 ( PascalFrancis/Curation ); précédent : 001175; suivant : 001177

COMT inhibitors in Parkinson's disease

Auteurs : J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada]

Source :

Canadian journal of neurological sciences [ 0317-1671 ] ; 1999.

RBID : Pascal:99-0456197

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Inhibiteur enzyme, Catechol O-methyltransferase, Hépatite, Entacapone, Tolcapone, Chimiothérapie, Traitement, Toxicité, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Catechol O-methyltransferase, Chemotherapy, Entacapone, Enzyme inhibitor, Hepatitis, Human, Parkinson disease, Tolcapone, Toxicity, Treatment.

A01	`01`	`1`		`@0 0317-1671`
A02	`01`			`@0 CJNSA2`
A03		`1`		`@0 Can. j. neurol. sci.`
A05				`@2 26`
A06				`@3 SUP2`
A08	`01`	`1`	`ENG`	`@1 COMT inhibitors in Parkinson's disease`
A09	`01`	`1`	`ENG`	`@1 Parkinson's Disease: Challenges and New Advances: Presentations of a series of regional educational programs in 1998`
A11	`01`	`1`		`@1 RIVEST (J.)`
A11	`02`	`1`		`@1 BARCLAY (C. L.)`
A11	`03`	`1`		`@1 SUCHOWERSKY (O.)`
A14	`01`			`@1 Centre Universitaire de Santé de l'Estrie @2 Fleurimont, Quebec @3 CAN @Z 1 aut.`
A14	`02`			`@1 University of Ottawa @2 Ottawa, Ontario @3 CAN @Z 2 aut.`
A14	`03`			`@1 University of Calgary @2 Calgary, Alberta @3 CAN @Z 3 aut.`
A20				`@2 S34-S38`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A24	`01`			`@0 fre`
A43	`01`			`@1 INIST @2 17449 @5 354000089421960060`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 99-0456197`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Canadian journal of neurological sciences`
A66	`01`			`@0 CAN`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 04`
C03	`02`	`X`	`ENG`	`@0 Enzyme inhibitor @5 04`
C03	`02`	`X`	`SPA`	`@0 Inhibidor enzima @5 04`
C03	`03`	`X`	`FRE`	`@0 Catechol O-methyltransferase @2 FE @5 05 @6 Catechol «O»-methyltransferase`
C03	`03`	`X`	`ENG`	`@0 Catechol O-methyltransferase @2 FE @5 05 @6 Catechol «O»-methyltransferase`
C03	`03`	`X`	`SPA`	`@0 Catechol O-methyltransferase @2 FE @5 05 @6 Catechol «O»-methyltransferase`
C03	`04`	`X`	`FRE`	`@0 Hépatite @5 07`
C03	`04`	`X`	`ENG`	`@0 Hepatitis @5 07`
C03	`04`	`X`	`SPA`	`@0 Hepatitis @5 07`
C03	`05`	`X`	`FRE`	`@0 Entacapone @2 NK @2 FR @5 10`
C03	`05`	`X`	`ENG`	`@0 Entacapone @2 NK @2 FR @5 10`
C03	`05`	`X`	`SPA`	`@0 Entacapona @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Tolcapone @2 NK @2 FR @5 13`
C03	`06`	`X`	`ENG`	`@0 Tolcapone @2 NK @2 FR @5 13`
C03	`06`	`X`	`SPA`	`@0 Tolcapona @2 NK @2 FR @5 13`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`09`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`09`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Methyltransferases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Methyltransferases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Transferases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Transferases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Transferases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Enzyme`
C07	`03`	`X`	`ENG`	`@0 Enzyme`
C07	`03`	`X`	`SPA`	`@0 Enzima`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`06`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`07`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`09`	`X`	`FRE`	`@0 Appareil digestif pathologie @5 53`
C07	`09`	`X`	`ENG`	`@0 Digestive diseases @5 53`
C07	`09`	`X`	`SPA`	`@0 Aparato digestivo patología @5 53`
C07	`10`	`X`	`FRE`	`@0 Foie pathologie @5 54`
C07	`10`	`X`	`ENG`	`@0 Hepatic disease @5 54`
C07	`10`	`X`	`SPA`	`@0 Hígado patología @5 54`
N21				`@1 291`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D47

Links to Exploration step

Pascal:99-0456197

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">COMT inhibitors in Parkinson's disease</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J." last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Universitaire de Santé de l'Estrie</s1>
<s2>Fleurimont, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C. L." last="Barclay">C. L. Barclay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0456197</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0456197 INIST</idno>
<idno type="RBID">Pascal:99-0456197</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001176</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">COMT inhibitors in Parkinson's disease</title>
<author><name sortKey="Rivest, J" sort="Rivest, J" uniqKey="Rivest J" first="J." last="Rivest">J. Rivest</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre Universitaire de Santé de l'Estrie</s1>
<s2>Fleurimont, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Barclay, C L" sort="Barclay, C L" uniqKey="Barclay C" first="C. L." last="Barclay">C. L. Barclay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Suchowersky, O" sort="Suchowersky, O" uniqKey="Suchowersky O" first="O." last="Suchowersky">O. Suchowersky</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Entacapone</term>
<term>Enzyme inhibitor</term>
<term>Hepatitis</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Tolcapone</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Inhibiteur enzyme</term>
<term>Catechol O-methyltransferase</term>
<term>Hépatite</term>
<term>Entacapone</term>
<term>Tolcapone</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0317-1671</s0>
</fA01>
<fA02 i1="01"><s0>CJNSA2</s0>
</fA02>
<fA03 i2="1"><s0>Can. j. neurol. sci.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s3>SUP2</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>COMT inhibitors in Parkinson's disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Parkinson's Disease: Challenges and New Advances: Presentations of a series of regional educational programs in 1998</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>RIVEST (J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BARCLAY (C. L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SUCHOWERSKY (O.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre Universitaire de Santé de l'Estrie</s1>
<s2>Fleurimont, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Ottawa</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s2>S34-S38</s2>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA24 i1="01"><s0>fre</s0>
</fA24>
<fA43 i1="01"><s1>INIST</s1>
<s2>17449</s2>
<s5>354000089421960060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0456197</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Canadian journal of neurological sciences</s0>
</fA64>
<fA66 i1="01"><s0>CAN</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>05</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>05</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>05</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Hépatite</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Hepatitis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hepatitis</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Entacapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Tolcapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tolcapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Appareil digestif pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>53</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Foie pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>54</s5>
</fC07>
<fN21><s1>291</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001176 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001176 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:99-0456197
   |texte=   COMT inhibitors in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

COMT inhibitors in Parkinson's disease

COMT inhibitors in Parkinson's disease

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri